Furthermore, CBD has been shown to inhibit migration, invasion, and epithelial‒mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) by suppressing the PI3K/AKT pathway [49]. Here, AKT1 is linked to non-small cell lung carcinoma.